New drug trial seeks right dose for Tough-to-Treat breast cancer
NCT ID NCT07311993
Summary
This early-stage study is testing a new drug called CLR 125 in people with advanced triple-negative breast cancer that has come back or stopped responding to other treatments. The main goals are to find the safest and most effective dose for future studies and to understand what side effects patients experience. About 60 participants will receive the drug through an IV every few weeks and be closely monitored.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic Florida
NOT_YET_RECRUITINGJacksonville, Florida, 32224, United States
Contact
-
United Theranostics
RECRUITINGGlen Burnie, Maryland, 21061, United States
Contact
Conditions
Explore the condition pages connected to this study.